Leveraging innate cell engagers for lymphoma treatment
European Pharmaceutical Review
DECEMBER 28, 2023
As a result, when the patient’s lymphoma relapses after treatment with chemotherapy, BV and CPIs, there are no effective treatment alternatives for these patients. We received encouraging feedback from the US Food and Drug Administration (FDA) on the trial design and potential for accelerated approval. Dr Harstrick received his M.D.
Let's personalize your content